*INVITE/SLIDES* Timeout with Tewari - Webcast TODAY (6/12) @ 9:30AM ET

Research evidence excerpt

*INVITE/SLIDES* Timeout with Tewari - Webcast TODAY (6/12) @ 9:30AM ET

ENTA mgmt. takeaways (2/2) – their STAT6 inhibitor can maintain trough levels

above EC90 and deliver 24hr STAT6 inhibition + EDP-798’s differentiation is on

tolerability & selectivity

• Mgmt highlighted emerging regulatory precedent for antiviral prophylaxis strategies, citing Shionogi's program as an example. Mgmt didn’t comment on development

timing, but acknowledged the attractiveness of a prophylaxis strategy.

• Mgmt noted they continue to view both RSV assets favorably and suggested future lifecycle management opportunities could include treatment, prophylaxis, and

potentially combination approaches over time.

STAT6 inhibitor (EDP-3903)

• Mgmt noted Kymera previously argued inhibitors lose efficacy as drug levels decline whereas degraders provide sustained target suppression. ENTA has

demonstrated sustained STAT6 inhibition over a 24-hour period, with trough concentrations remaining above the EC90 required for target blockade, and therefore does

not believe a degrader is required to achieve continuous pathway suppression. In mgmt’s view, degraders may have been needed before high-quality inhibitors were

available, but optimized inhibitors with adequate trough coverage can provide continuous pharmacologic inhibition.

• On tissue distribution, mgmt has evaluated tissue exposure across target organs and safety-relevant tissues. Mgmt argued small molecules generally distribute broadly

throughout intracellular and extracellular compartments, enabling access to tissue sites that can be difficult for other modalities to reach.

• On development strategy, mgmt highlighted atopic dermatitis as an attractive PoC indication given straightforward trial execution, rapid efficacy readouts, and